Oct 3 (Reuters) - Chinese biotech companies WuXi AppTec
and WuXi Biologics , which are being targeted by a forthcoming U.S. national security legislation, are working on sales of some of their operations, the Financial Times reported on Thursday, citing people familiar with the matter.
WuXi AppTec has put its cell and gene therapy manufacturing arm WuXi Advanced Therapies, which operates four laboratories and manufacturing facilities in Philadelphia, up for sale, the newspaper reported.
WuXi Biologics is also working with advisers to test interest in some of its European production facilities, FT reported, citing three people familiar with the situation.
(Reporting by Rishabh Jaiswal in Bengaluru; Editing by Sonia Cheema)
((rishabh.jaiswal@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。